History logo

Boots Sold to US Private Equity Firm in $10 Billion Deal

Big Changes for Boots: US Firm Buys the Pharmacy Chain for $10 Billion

By Rimon ParvezPublished 11 months ago 4 min read
Boots Sold to US Private Equity Firm in $10 Billion Deal
Photo by Microsoft Edge on Unsplash

The UK’s iconic pharmacy chain, Boots, is set for a significant change following the announcement that its parent company, Walgreens Boots Alliance (WBA), has agreed to sell the business to US private equity firm Sycamore Partners for $10 billion (£7.7 billion). Walgreens, which acquired Boots in 2014, has faced mounting pressures in recent years, including stiff competition from online retailers and reduced payments from health insurers. These factors have contributed to a sharp decline in Walgreens' share price. The deal values Walgreens at $11.45 per share, which represents an 8% premium over its last closing price. However, this is a significant drop from the $85 per share value in 2015 when the company was valued at over $90 billion. The sale has sparked concerns about the future of Boots' 1,900 UK stores and its large workforce, with many wondering what the future holds for one of the country’s most recognized pharmacy brands.

---

Why Is Walgreens Selling Boots?

Boots has long been a staple in the British retail landscape, serving customers with pharmacy services, health products, and beauty items for nearly 175 years. However, in recent times, the company has struggled to keep pace with the shift to online shopping. Consumers are increasingly purchasing medications, cosmetics, and health products from e-commerce giants like Amazon, reducing foot traffic to physical stores. Additionally, cuts in NHS funding for pharmacies have further impacted profitability, particularly for both independent and chain pharmacies.

Dr. Leyla Hannbeck, CEO of the Independent Pharmacies Association, has raised concerns that Boots could face significant store closures under its new owners. She remarked: "If NHS community pharmacy funding remains as poor as it is now, the new buyers may choose to shut down unprofitable Boots locations."

Despite these challenges, Walgreens' international chief, Ornella Barra, reassured employees that “nothing is changing” for the time being. In an internal email, she emphasized that Sycamore’s investment is a sign of confidence in Boots’ role in healthcare, retail, and local communities.

---

Who Is Sycamore Partners?

Sycamore Partners, a US-based private equity firm, specializes in retail and consumer-focused businesses. The firm has a notable track record of acquiring prominent companies, including the $7 billion purchase of Staples in 2017. It has also made investments in fashion brands such as Kurt Geiger and has shown interest in companies like Ted Baker.

The deal includes a 35-day "go-shop" period, which allows Walgreens to consider alternative offers. However, analysts believe it is unlikely another bidder will emerge, making it almost certain Sycamore will take ownership. The acquisition is expected to be completed by late 2025.

---

What Does This Mean for Boots Customers?

For the time being, Boots customers will not experience immediate changes in the operation of the stores. The pharmacy, optician, and beauty services will continue as usual. However, there are concerns that Sycamore, as a private equity firm, may seek to cut costs and improve profitability, potentially leading to the closure of underperforming stores.

Walgreens CEO Tim Wentworth suggested that taking Boots private would allow for better restructuring: "Our trusted brands and deep commitment to our customers, patients, and communities will continue to anchor our business as we move forward."

Sycamore’s managing director, Stefan Kaluzny, expressed confidence in Boots' "pharmacy-led model," acknowledging the vital role the company plays in local communities.

---

Could Some Boots Stores Be at Risk?

While Sycamore has voiced support for Boots’ business model, many industry experts and employees remain cautious. Private equity firms are often known for restructuring businesses to maximize profitability, which could mean store closures, layoffs, or changes in product offerings. The broader trend of the decline in traditional high street retail also poses challenges, as online shopping continues to erode foot traffic. To stay competitive, Boots may need to invest in digital services, enhance in-store experiences, and offer exclusive products.

Retail analyst Michael Cherny expressed surprise at the sale, saying: “It actually happened.” Previously, Walgreens had struggled to find a buyer for Boots, making the current deal a significant shift for the company.

---

What’s Next for Boots?

Although no immediate changes are expected, the future direction of Boots under Sycamore’s ownership remains uncertain. The firm may choose to invest in digital transformation, modernize stores, or expand pharmacy services. Alternatively, Sycamore could focus on cost-cutting measures, potentially closing underperforming locations.

One possibility is that Boots could enhance its healthcare offerings by introducing in-store clinics, prescription delivery services, and personalized health consultations. This could help differentiate Boots from its online competitors and strengthen its position in the market.

The question also arises as to whether Boots will remain privately owned for the long term. Private equity firms typically acquire businesses, restructure them, and later sell them for a profit. Therefore, it is possible that Boots could change hands again in the near future.

For now, Boots’ customers and employees must wait and see how this acquisition unfolds. If Sycamore invests in innovation and service improvements, Boots could continue to thrive as a leading pharmacy and retail brand. However, if cost-cutting measures take precedence, the UK may witness further closures of high street stores. The future of one of Britain’s most beloved pharmacy chains remains in the balance as the retail industry undergoes rapid transformation.

AnalysisWorld HistoryModern

About the Creator

Rimon Parvez

I am Rimon.

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2026 Creatd, Inc. All Rights Reserved.